BIO-TECHNE CORP shareholders Q2 2022

BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 540 filers reported holding BIO-TECHNE CORP in Q2 2022. The put-call ratio across all filers is 0.42 and the average weighting 0.2%.

BIO-TECHNE CORP shareholders Q2 2022
NameSharesValueWeighting ↓
Palisade Asset Management, LLC 14,216$4,928,0000.63%
Arabesque Asset Management Ltd 3,414$1,183,0000.62%
LEAVELL INVESTMENT MANAGEMENT, INC. 20,641$7,155,0000.55%
Yorktown Management & Research Co Inc 1,200$416,0000.54%
Legacy Wealth Asset Management, LLC 3,380$1,172,0000.48%
MCKINLEY CAPITAL MANAGEMENT LLC 10,230$3,546,0000.46%
Paradigm, Strategies in Wealth Management, LLC 1,208$419,0000.46%
Formidable Asset Management, LLC 5,771$2,004,0000.45%
TWINBEECH CAPITAL LP 27,593$9,565,0000.43%
Conestoga Capital Advisors, LLC 64,419$22,330,0000.41%
Quadrature Capital Ltd 25,878$8,981,0000.38%
Neuberger Berman Group LLC 1,045,789$362,514,0000.36%
DUALITY ADVISERS, LP 10,020$3,473,0000.34%
ROYCE & ASSOCIATES LP 95,860$33,229,0000.34%
MARSHALL WACE, LLP 448,038$155,310,0000.32%
SNYDER CAPITAL MANAGEMENT L P 31,937$11,071,0000.30%
BEACON INVESTMENT ADVISORY SERVICES, INC. 16,246$5,632,0000.29%
Quantbot Technologies LP 9,041$3,133,0000.29%
EAGLE ASSET MANAGEMENT INC 128,160$44,425,0000.28%
THRIVENT FINANCIAL FOR LUTHERANS 302,079$104,712,0000.28%
About BIO-TECHNE CORP

Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.

Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.

In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.

Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.

Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.

It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.

External links

This page lists BIO-TECHNE CORP's shareholders in Q2 2022. To view BIO-TECHNE CORP's shareholder history, click here.